fbpx

Year

2016
TED is a rare condition suffered by a proportion of Graves’ Disease patients. Characterized by inflammation and a build up of tissue behind the eye, the disease causes the eyeball to protrude from the socket.  This can change the patient’s appearance and result in orbital pain, corneal ulceration, optic neuropathy and double vision among other...
The paper provides 12-34 month follow up data from the first 100 patients in a prospective study evaluating CERAMENT G for dead space (void) management in patients with chronic osteomyelitis (bone infection) using a single stage surgical procedure. These data showed that this approach, augmented by the use of CERAMENT G, was highly effective, delivering...
The EBJIS annual meeting will feature 25 abstracts highlighting research and clinical findings with CERAMENT G and CERAMENT V. This is a significant increase in the number of presentations and posters that were made at the 34th Annual EBIJS meeting reflecting the impressive clinical performance reported, the launch of CERAMENT V in 2016 and the...
Dr Julian Gilbert, Acacia Pharma’s CEO commented: “We are delighted with these data demonstrating that BAREMSIS is safe and effective at treating patients suffering PONV after surgery. It confirms our confidence in the dopamine antiemetic mechanism of action, and that BAREMSIS is effective at treating, as well as preventing, PONV. Our objective is to seek...
According to Fares Zahir, CEO of Xeraya Capital, “Our enthusiasm for Iconic rests in its novel approach to developing therapies for devastating diseases such as macular degeneration and cancer. In particular, the tissue factor-based platform gives the Company the opportunity to interrogate a target that has proven elusive in the past. We believe the early...
The FORTIFY study, a randomized multicenter controlled trial, will evaluate the safety and efficacy of CERAMENT G as part of surgical repair of open diaphyseal tibial fractures. The trial will enrol up to 230 patients at up to 30 centers globally, with the aim of having at least 50% of the study data coming from...
All Series A investors contributed to the financing extension, including Alexandria Venture Investments, Bay City Capital LLC, Lundbeckfond Ventures, New Enterprise Associates (NEA), and Pfizer Venture Investments. Together with proceeds from the original Series A announced in January of 2015, Vtesse has raised a total of $42 million to fund development of its lead product...
Jack A. Khattar is the founder of Supernus Pharmaceuticals (NASDAQ:SUPN) and has served as president and Chief Executive Officer and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including Board Member, president and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar...
Enadenotucirev is designed to have immune stimulating effects while Opdivo is designed to alleviate immune suppression. The clinical collaboration will support Phase 1 studies to determine whether combining these two agents can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses. “This collaboration continues...
Researchers at the University of Copenhagen have discovered a molecular mechanism that reads so-called epigenetic information and boosts repair of lesions in our DNA. This knowledge can be used to develop new targeted cancer treatment in which “inhibitor molecules” can prevent cancer cells from repairing themselves. The researchers have taken out a patent for their...
1 2 3 4 5 8

Nyheder

New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge